AstraZeneca plans to build a commercial cell therapy manufacturing base in the Lin-gang Special Area of the Shanghai Free Trade Zone to supply autologous CAR-T therapies like AZD0120 to China and Asia. 1 2 7 A new innovation center in Zhangjiang High-Tech Park will focus on early-stage research, viral vector development, analytical testing, clinical batch production, and registration support. 1 2 5 This makes AstraZeneca the first multinational pharma with end-to-end cell therapy capabilities in China, part of a $15 billion investment pledge through 2030. 1 2 Announcement made on March 19, 2026, aligning with recent China formulary inclusion of CAR-T products and UK-Shanghai collaboration. 1 4 AstraZeneca generated $6.7 billion in China revenue in 2025 and operates existing R&D centers and manufacturing bases there. 1 Sources: 1. https://www.fiercebiotech.com/pharma/astrazeneca-build-cell-therapy-manufacturing-hub-rd-center-shanghai 2. https://www.biospace.com/busines...
- Get link
- X
- Other Apps